This slide show features various images of papillary, clear cell, chromophobe, and tubulocystic renal cell carcinoma.
Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy
David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.
Unveiling Advances in GU Cancers: Insights from Oncology Decoded
Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
Potential Biomarker May Predict Outcomes/Response in RCC
A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.
A Sneak Peek at 2025 ASCO From the GU Perspective
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.
Pembrolizumab Combo Yields Enduring Activity in Advanced Non-Clear Cell RCC
Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
Metastasis-Directed RT Without Systemic Therapy Improved Efficacy in RCC
Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.